A prospective randomized trial of idarubicin vs daunorubicin in combination chemotherapy for acute myelogenous leukemia of the age group 55 to 75.
Reiffers J, Huguet F, Stoppa AM, Molina L, Marit G, Attal M, Gastaut JA, Michallet M, Lepeu G, Broustet A, Pris J, Maraninchi D, Hollard D, Fabères C, Mercier M, Hurteloup P, Danel P, Tellier Z, Berthaud P.
Reiffers J, et al. Among authors: hurteloup p.
Leukemia. 1996 Mar;10(3):389-95.
Leukemia. 1996.
PMID: 8642852
Clinical Trial.